Showing 1861-1870 of 9944 results for "".
First Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/series/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testingWhy Are Dermatologists Not Writing Biologics?
https://practicaldermatology.com/topics/practice-management/why-are-dermatologists-inoti-writing-biologics/23427/Biologics have been shown to be both safe and effective for a variety of indications, so why don’t more dermatologists prescribe them?Everything Old Is New Again: Re-assessing IPL
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/everything-old-is-new-again-re-assessing-ipl/23013/Long-term IPL use may turn the tables on aging skin.Impetigo: An Unconventional Case Report
https://practicaldermatology.com/topics/rare-disease/impetigo-an-unconventional-case-report/26246/Mauri Hart, a medical student at the Oklahoma State University College of Osteopathic Medicine, takes a look at a unique case study, and tests the reader's knowledge of impetigo.Meet the New Crop of Pigment Correctors
https://practicaldermatology.com/topics/pigmentary-disorders/meet-the-new-crop-of-pigment-correctors/23767/Hydroquinone is no longer the only game in town. In fact, alternatives are now more readily available and show good efficacy.How Physicians Are Unlike Most US Investors
https://practicaldermatology.com/topics/practice-management/how-physicians-are-unlike-most-us-investors/23370/A look at how the difference in the tax situations of physicians and average retail investors, and why these differences matter.Phase 2 and 3 Trials of JAK Inhibitors For Atopic Dermatitis: A Review
https://practicaldermatology.com/topics/atopic-dermatitis/phase-2-and-3-trials-of-jak-inhibitors-for-atopic-dermatitis-a-review/23265/A number of drugs in development show promise for one of the most challening skin diseases.Bonus and Incentive Programs
https://practicaldermatology.com/topics/practice-management/bonus-and-incentive-programs/20918/Profit-sharing legalities and potential pitfalls.New Advancements in Microneedle Resurfacing
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-advancements-in-microneedle-resurfacing/21354/Microneedle resurfacing has quickly become one of the most in-demand aesthetic procedures, likely due to its strong results, quick healing times, and cost-effectiveness.Taking the Pulse of Hydroquinone Therapy: A Plea for Caution
https://practicaldermatology.com/topics/general-topics/taking-the-pulse-of-hydroquinone-therapy-a-plea-for-caution/22946/Pulse therapy under physician supervision can reduce long-term exposure and help reduce the risk of untoward effects of hydroquinone therapy.